“We will begin the international rollout of Libre Duo in the fall and we look forward to bringing this innovative new technology to the United States market After we obtain FDA approval.”

In context

“iving growth of more than 20% in Europe. Remain confident in our outlook for the second half of the year, including our expectations to begin outperforming the market and recapturing share. In Rhythm Management, sales grew 9.5% as we continue to expand the use of Avera across both the single and dual chamber segments of pacemaker market and to drive broader adoption of this innovative technology In heart failure, growth of 9% was led by double-digit growth in the US, driven by our market leading portfolio of heart assist devices that address both chronic and acute patient needs. In diabetes care, continuous glucose monitoring sales exceeded $2 billion, reflecting growth of 9.5% in the quarter. In May, we secured CE Mark for Libre Duo, the world's first dual glucose ketone wearable sensor. We will begin the international rollout of Libre Duo in the fall and we look forward to bringing this innovative new technology to the United States market After we obtain FDA approval. So, in summary, we remain highly focused on disciplined execution in each quarter. Our second quarter results represent an important building block as we move into the second half of the year. We have momentum building across the portfolio and have a clear line of sight to the key drivers of sales growth acceleration that are forecasted in the second half. Our continued focus on gross margin expansion gives us confidence in raising our full year EPS guidance. And we have several new products that we anticipate launching at a steady cadence over the next 12 months. I will turn the call over to Philip. Philip Boudreau: Thanks, Robert. As Mike mentioned earlier, please note that all references to sales growth rates, unless otherwise noted, are on a comparable basis. Turning to our second qua”